Three Remain Liable On UK Liothyronine Price Abuse – But Fines Slimmed On Appeal
Advanz Pharma Loses Both Liability And Fine Appeals, Deemed ‘Unimpeachable’
Advanz Pharma has failed in its appeal against a £40.9m fine imposed by the UK’s Competition and Markets Authority for its historical pricing practices for liothyronine tablets.
